Kura Oncology’s (KURA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report report published on Wednesday,Benzinga reports. HC Wainwright currently has a $32.00 price objective on the stock.

A number of other brokerages have also commented on KURA. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and decreased their price objective for the company from $26.00 to $19.00 in a research report on Monday, October 14th. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. UBS Group initiated coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. Finally, JMP Securities reissued a “market outperform” rating and issued a $32.00 price target on shares of Kura Oncology in a research note on Monday, August 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Price Performance

Shares of KURA traded down $0.09 on Wednesday, hitting $17.68. The company’s stock had a trading volume of 687,009 shares, compared to its average volume of 660,457. The company has a 50 day moving average price of $18.78 and a 200 day moving average price of $19.99. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02. Kura Oncology has a fifty-two week low of $8.17 and a fifty-two week high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. During the same quarter in the prior year, the company earned ($0.53) earnings per share. Kura Oncology’s revenue was up .0% on a year-over-year basis. As a group, sell-side analysts anticipate that Kura Oncology will post -2.46 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Kura Oncology by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after acquiring an additional 28,212 shares during the period. Avoro Capital Advisors LLC grew its stake in Kura Oncology by 29.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after buying an additional 870,000 shares during the last quarter. Armistice Capital LLC raised its holdings in Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after acquiring an additional 302,000 shares during the period. Artal Group S.A. lifted its position in Kura Oncology by 8.6% during the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock worth $40,951,000 after acquiring an additional 151,828 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of Kura Oncology by 50.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after purchasing an additional 577,732 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.